AstraZeneca's stock experienced a significant decline of over 4% on Monday due to uncertainties surrounding the future of CEO Pascal Soriot, as reported in the news. Initially, the company refrained from commenting on the report but later clarified that they do not engage in discussions regarding market rumors. Their shares, listed as NASDAQ: AZN, closed down...
During Covid-19, the market significantly dropped in price. Post this retracement, the market recovered swiftly. With many indicators such as inverted treasury yields pointing towards an impending recession, we form the following view on the S&P500.
We envisage the market to drop significantly during the coming months and see the marked investment zone is a good...
Accumulation or distribution? Wychoff wants to know! Phase C, Spring Stage? M.Cap is below CASH, Best in Class vaccine with over 43+ International Approvals.
It’s just amazing what Nova’s teams have be able to accomplish(for its size) around the globe!
the inability of NVAX to properly capitalize on the covid vaccine is a sign of a poorly managed company. was the rise from near penny status exceptional? of course. was the following wealth destruction of epic proportions? sure was.
endless upset longs continue to exit as all good news acts as a selling event. this will be a ride back to single digits for a...
We have a long-term weekly EUR/USD double bottom on the horizon. Although it’s more than a 100 pips off, it never hurts to be prepared:
COVID-19 Double Bottom, 1.0635-37
Here's the trade:
1) Buy 1.0655
2) Initial Stop Loss @ 1.0594
3) 1:1 Risk vs Reward, Profit Target @ 1.0716
as we see it's counterpart - gold - losing steam,
we can see a turn-around in pound aussie pair.
also usd bullish strength will help this pair.
we also see economic news for aussie - rba meeting minutes which can impact this pair.
mar 14th - 20th aiming for $1.81 or above.
1. Failed to break $160 ( three times)
2. RSI strong negative divergence.
3. Elliot Wave Complete
4.fibonacci 161% is at around $115 level
1. Long-term Covid effects in this industry
2. Higher Inflation. Increasing oil prices will further hit the industry negatively!
3. Company's debt is very high, lower operating margin....
This idea leans a bit more on speculation, but it is something that's crossed my mind recently.
Given the IMF practicing for cyber-attacks specifically aimed at the global financial system, it gives worry of a covid like crash that'll break support at 30k.
Not to mention how close the current price action is now resembling the price action of back in March...
Previously (see linked idea), the MACD model projected " a new wave should be approaching and happening in India in December 2021, going into 2022."
This was back in October 20, 2021
Just started as expected! Seen that the last week of 2021 and first week in 2022 is registering a spike, and a greater spike following.
Albeit the spike is not as pronounced yet,...
It's time to wrap up 2021 and outline what has happened based on an analysis of S&P500 as a major index.
At first glance (and as the title suggests) covid stayed with us throughout the whole year causing volatility in the market. Average correction caused by C19 and its new variants equaled 4.95%, with the biggest decrease of 5.7% caused by the Delta...
Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants...
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants.
- The companies announced...
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory...
Not financial advice!
With the new corona variant spreading fear all over the world, PFE and MRNA are running. I think it's possible for MRNA to reclaim the bullish channel, aka the Bull-Trap that broke down, when PFE announced the Paxlovid-med. I got in MRNA way to late, now taking a risky trade, since MRNA gaps like crazy, and there's always the chance that...
$MRNA $308 or $300 bounce
(If we get below then reclaim these levels, take a position for calls)
Technical analysis: Bounce off pivot point around 308 area or bounce off psychological level at 300
Rationale: With increasing news of a new virus variant, vaccine stocks are rallying so there is built up potential for more momentum